{"classes":[{"categories":[{"measurements":[{"comment":"Median and 95% confidence interval (CI) were not available due to censoring.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median and upper limit of 95% CI were not available due to censoring.","groupId":"OG001","lowerLimit":"27.3","upperLimit":"NA","value":"NA"},{"comment":"Median and 95% CI were not available due to censoring.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"description":"Duration of MMR/MR3 was defined as the interval between the first assessment at which the criteria for \\<=0.1% MMR were met until the earliest date at which loss of \\<=0.1% MMR occurred, or the criteria for progression were met. Progression to accelerated phase (AP) was defined as: \\>= 15% and \\<30% blasts in peripheral blood or bone marrow or \\>=20% basophils in peripheral blood or bone marrow or \\>=30% blasts + promyelocytes in peripheral blood or bone marrow (but \\<30% blasts) or \\<100\\*109 platelets per liter (/L) in peripheral blood unrelated to therapy or cytogenetic, genetic evidence of clonal evolution, and no extramedullary disease. Progression to blast phase (BP) was defined as: \\>=30% blasts in peripheral blood or bone marrow or extramedullary disease other than hepatosplenomegaly.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received ponatinib 45 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.","id":"OG000","title":"Treatment Period: Cohort A: Ponatinib 45 mg"},{"description":"Participants received ponatinib 30 mg orally once daily in each 28-day cycle until achievement of ≤1% BCR-ABL1IS. Once ≤1% BCR-ABL1IS was achieved, participants received reduced dose of ponatinib 15 mg orally once daily.","id":"OG001","title":"Treatment Period: Cohort B: Ponatinib 30 mg"},{"description":"Participants received ponatinib 15 mg orally once daily in each 28-day cycle.","id":"OG002","title":"Treatment Period: Cohort C: Ponatinib 15 mg"}],"paramType":"MEDIAN","populationDescription":"ITT Population included all participants who were randomized and for whom BCR-ABL1IS could be measured (i.e., participants who had the b2a2/b3a2 transcript type), regardless of whether they received the assigned study drug. Overall number of participants analyzed is the number of participants with MR3.","reportingStatus":"POSTED","timeFrame":"Baseline up to approximately 8.9 years","title":"Duration of Major Molecular Response (MMR/MR3)","type":"SECONDARY","unitOfMeasure":"months"}